BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 12712403)

  • 1. LuCaP 35: a new model of prostate cancer progression to androgen independence.
    Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL
    Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.
    Ellis WJ; Vessella RL; Buhler KR; Bladou F; True LD; Bigler SA; Curtis D; Lange PH
    Clin Cancer Res; 1996 Jun; 2(6):1039-48. PubMed ID: 9816265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.
    Corey E; Quinn JE; Emond MJ; Buhler KR; Brown LG; Vessella RL
    Clin Cancer Res; 2002 Apr; 8(4):1003-7. PubMed ID: 11948106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
    Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
    Harper ME; Goddard L; Smith C; Nicholson RI
    Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
    Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
    Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
    Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of seven new human prostate tumor xenograft models and their histopathological characterization.
    van Weerden WM; de Ridder CM; Verdaasdonk CL; Romijn JC; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Am J Pathol; 1996 Sep; 149(3):1055-62. PubMed ID: 8780407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel method of generating prostate cancer metastases from orthotopic implants.
    Corey E; Quinn JE; Vessella RL
    Prostate; 2003 Jul; 56(2):110-4. PubMed ID: 12746835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the androgen receptor pathway during progression of prostate cancer.
    Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
    Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
    Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
    Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
    Linja MJ; Savinainen KJ; Saramäki OR; Tammela TL; Vessella RL; Visakorpi T
    Cancer Res; 2001 May; 61(9):3550-5. PubMed ID: 11325816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interrogating androgen receptor function in recurrent prostate cancer.
    Zhang L; Johnson M; Le KH; Sato M; Ilagan R; Iyer M; Gambhir SS; Wu L; Carey M
    Cancer Res; 2003 Aug; 63(15):4552-60. PubMed ID: 12907631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.
    Craft N; Chhor C; Tran C; Belldegrun A; DeKernion J; Witte ON; Said J; Reiter RE; Sawyers CL
    Cancer Res; 1999 Oct; 59(19):5030-6. PubMed ID: 10519419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.